938 related articles for article (PubMed ID: 16859511)
1. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells.
Galliher AJ; Schiemann WP
Breast Cancer Res; 2006; 8(4):R42. PubMed ID: 16859511
[TBL] [Abstract][Full Text] [Related]
2. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
Galliher AJ; Schiemann WP
Cancer Res; 2007 Apr; 67(8):3752-8. PubMed ID: 17440088
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
4. Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Galliher-Beckley AJ; Schiemann WP
Carcinogenesis; 2008 Feb; 29(2):244-51. PubMed ID: 18174260
[TBL] [Abstract][Full Text] [Related]
5. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta.
Sokol JP; Neil JR; Schiemann BJ; Schiemann WP
Breast Cancer Res; 2005; 7(5):R844-53. PubMed ID: 16168131
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Expression of Integrin αvβ3 Induced by TGF-β Is Required for the Enhancing Effect of Fibroblast Growth Factor 1 (FGF1) in TGF-β-Induced Epithelial-Mesenchymal Transition (EMT) in Mammary Epithelial Cells.
Mori S; Kodaira M; Ito A; Okazaki M; Kawaguchi N; Hamada Y; Takada Y; Matsuura N
PLoS One; 2015; 10(9):e0137486. PubMed ID: 26334633
[TBL] [Abstract][Full Text] [Related]
7. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II.
Maeda M; Shintani Y; Wheelock MJ; Johnson KR
J Biol Chem; 2006 Jan; 281(1):59-68. PubMed ID: 16267045
[TBL] [Abstract][Full Text] [Related]
8. Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells.
Taylor MA; Amin JD; Kirschmann DA; Schiemann WP
Neoplasia; 2011 May; 13(5):406-18. PubMed ID: 21532881
[TBL] [Abstract][Full Text] [Related]
9. Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Int J Oncol; 2011 Mar; 38(3):797-805. PubMed ID: 21225226
[TBL] [Abstract][Full Text] [Related]
10. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
[TBL] [Abstract][Full Text] [Related]
11. Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism.
Lee YH; Albig AR; Regner M; Schiemann BJ; Schiemann WP
Carcinogenesis; 2008 Dec; 29(12):2243-51. PubMed ID: 18713838
[TBL] [Abstract][Full Text] [Related]
12. p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity.
Wendt MK; Smith JA; Schiemann WP
J Biol Chem; 2009 Dec; 284(49):34145-56. PubMed ID: 19822523
[TBL] [Abstract][Full Text] [Related]
13. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
14. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells.
Taylor MA; Parvani JG; Schiemann WP
J Mammary Gland Biol Neoplasia; 2010 Jun; 15(2):169-90. PubMed ID: 20467795
[TBL] [Abstract][Full Text] [Related]
15. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene.
Lam S; Wiercinska E; Teunisse AF; Lodder K; ten Dijke P; Jochemsen AG
Breast Cancer Res Treat; 2014 Nov; 148(1):7-18. PubMed ID: 25257729
[TBL] [Abstract][Full Text] [Related]
17. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
18. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity.
Bhowmick NA; Zent R; Ghiassi M; McDonnell M; Moses HL
J Biol Chem; 2001 Dec; 276(50):46707-13. PubMed ID: 11590169
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
Wang SE; Wu FY; Shin I; Qu S; Arteaga CL
Mol Cell Biol; 2005 Jun; 25(11):4703-15. PubMed ID: 15899872
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta control of cell proliferation.
Huang SS; Huang JS
J Cell Biochem; 2005 Oct; 96(3):447-62. PubMed ID: 16088940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
